Alzamend Neuro announces completion of head coil by Tesla Dynamic Coils

Alzamend Neuro (ALZN) announced the completion of a head coil by Tesla Dynamic Coils. The development of the head coil was necessary to facilitate the five upcoming Phase II clinical trials to be conducted by Alzamend. In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend intends to undertake pioneering clinical trials, with a goal to assess how lithium levels in the brain differ when using AL001 compared to marketed lithium salts, both in healthy individuals and patients with Alzheimer’s, BD, MDD and PTSD. The head coil will enable whole-brain imaging of lithium with remarkable resolution, allowing precise quantification within brain structures. The coil will be used to help identify the disease-specific target doses of AL001 that improve the balance of safety and efficacy compared to lithium carbonate. The coil will also be used to scan the entire brain.